Monica M Mita1, Anil A Joy2, Alain Mita3, Kamalesh Sankhala3, Ying-Ming Jou4, Da Zhang4, Paul Statkevich4, Yali Zhu4, Siu-Long Yao4, Karen Small4, Rajat Bannerji4, Charles L Shapiro5. 1. The University of Texas Health Science Center, San Antonio, TX. Electronic address: monica.mita@cshs.org. 2. Division of Medical Oncology, Department of Oncology, Cross Cancer Institute, University of Alberta, Edmonton, Canada. 3. The University of Texas Health Science Center, San Antonio, TX. 4. Merck & Co., Inc., Whitehouse Station, NJ. 5. Wexner Medical Center, The Ohio State University, Columbus, OH.
Abstract
INTRODUCTION: Effective therapies after failure of treatment with anthracyclines and taxanes are needed for patients with metastatic breast cancer. Dinaciclib (MK-7965, formerly SCH727965), a small-molecule cyclin-dependent kinase inhibitor, has demonstrated antitumor activity in phase I studies with solid-tumor patients. This phase II trial was designed to assess the efficacy and safety of dinaciclib compared with that of capecitabine in women with previously treated advanced breast cancer. PATIENTS AND METHODS: Patients were randomized to receive either dinaciclib at 50 mg/m(2), administered as a 2-hour infusion every 21 days, or 1250 mg/m(2) capecitabine, administered orally twice daily in 21-day cycles. RESULTS: An unplanned interim analysis showed that the time to disease progression was inferior with dinaciclib treatment compared with capecitabine treatment; therefore, the trial was stopped after 30 patients were randomized. Dinaciclib treatment demonstrated antitumor activity in 2 of 7 patients with estrogen receptor-positive and human epidermal growth factor receptor 2-negative metastatic breast cancer (1 confirmed and 1 unconfirmed partial response), as well as acceptable safety and tolerability. Grade 3 or 4 treatment-related adverse events were common and included neutropenia, leukopenia, increase in aspartate aminotransferase, and febrile neutropenia. Population pharmacokinetic model-predicted mean dinaciclib exposure (area under the concentration-time curve extrapolated to infinity [AUC[I]]) at 50 mg/m(2) was similar to that observed in a previous phase I trial, and no drug accumulation was observed after multiple-dose administration. CONCLUSION: Although dinaciclib monotherapy demonstrated some antitumor activity and was generally tolerated, efficacy was not superior to capecitabine. Future studies may be considered to evaluate dinaciclib in select patient populations with metastatic breast cancer and in combination with other agents.
RCT Entities:
INTRODUCTION: Effective therapies after failure of treatment with anthracyclines and taxanes are needed for patients with metastatic breast cancer. Dinaciclib (MK-7965, formerly SCH727965), a small-molecule cyclin-dependent kinase inhibitor, has demonstrated antitumor activity in phase I studies with solid-tumorpatients. This phase II trial was designed to assess the efficacy and safety of dinaciclib compared with that of capecitabine in women with previously treated advanced breast cancer. PATIENTS AND METHODS: Patients were randomized to receive either dinaciclib at 50 mg/m(2), administered as a 2-hour infusion every 21 days, or 1250 mg/m(2) capecitabine, administered orally twice daily in 21-day cycles. RESULTS: An unplanned interim analysis showed that the time to disease progression was inferior with dinaciclib treatment compared with capecitabine treatment; therefore, the trial was stopped after 30 patients were randomized. Dinaciclib treatment demonstrated antitumor activity in 2 of 7 patients with estrogen receptor-positive and humanepidermal growth factor receptor 2-negative metastatic breast cancer (1 confirmed and 1 unconfirmed partial response), as well as acceptable safety and tolerability. Grade 3 or 4 treatment-related adverse events were common and included neutropenia, leukopenia, increase in aspartate aminotransferase, and febrile neutropenia. Population pharmacokinetic model-predicted mean dinaciclib exposure (area under the concentration-time curve extrapolated to infinity [AUC[I]]) at 50 mg/m(2) was similar to that observed in a previous phase I trial, and no drug accumulation was observed after multiple-dose administration. CONCLUSION: Although dinaciclib monotherapy demonstrated some antitumor activity and was generally tolerated, efficacy was not superior to capecitabine. Future studies may be considered to evaluate dinaciclib in select patient populations with metastatic breast cancer and in combination with other agents.
Authors: Ye Han; Yongkun Wei; Jun Yao; Yu-Yi Chu; Chia-Wei Li; Jennifer L Hsu; Lei Nie; Mien-Chie Hung Journal: Am J Cancer Res Date: 2020-04-01 Impact factor: 6.166
Authors: Shawn F Johnson; Cristina Cruz; Ann Katrin Greifenberg; Sofia Dust; Daniel G Stover; David Chi; Benjamin Primack; Shiliang Cao; Andrea J Bernhardy; Rhiannon Coulson; Jean-Bernard Lazaro; Bose Kochupurakkal; Heather Sun; Christine Unitt; Lisa A Moreau; Kristopher A Sarosiek; Maurizio Scaltriti; Dejan Juric; José Baselga; Andrea L Richardson; Scott J Rodig; Alan D D'Andrea; Judith Balmaña; Neil Johnson; Matthias Geyer; Violeta Serra; Elgene Lim; Geoffrey I Shapiro Journal: Cell Rep Date: 2016-11-22 Impact factor: 9.423
Authors: Daniel R Premkumar; Esther P Jane; Swetha Thambireddy; Philip A Sutera; Jonathon M Cavaleri; Ian F Pollack Journal: Mol Carcinog Date: 2017-12-30 Impact factor: 4.784